Island Pharmaceuticals Ltd (ASX:ILA) is an antiviral therapeutics company targeting infectious diseases. June has been a productive month for the company with five ASX announcements related to operationally meaningful developments around Galidesivir, while also reminding the market that ISLA-101 remains a secondary source of strategic optionality. The three most important announcements were: 1. the commencement of GMP manufacturing for Galidesivir; 2. the expansion of the CRADA with USAMRIID and The Geneva Foundation to support the coming non-human primate (NHP) dose-optimisation study; and 3. Galidesivir receiving Orphan Drug Designation by the US Food and Drug Administration (FDA). The first two announcements reduce execution risk around the FDA Animal Rule pathway. The June investor presentation was notable in its framing of Galidesivir as a multi-filovirus countermeasure opportunity given it’s a broad-acting antiviral capable of addressing multiple filovirus threats. ILA stresses Galidesivir’s competitive advantage vs. other drugs given it potentially has the broadest spectrum antiviral activity (in filoviruses and other families; timely given the current Ebola outbreak in the Democratic Republic of the Congo and Uganda). Finally, the Asia Dengue Summit presentation kept ILA’s second key asset ISLA-101 in focus, stressing ongoing discussions with multiple potential strategic partners to further Phase 2 and 3 clinical trials. While the June announcements reduce operational execution risk, they do not yet change the binary clinical or commercial endpoints that drive our valuation, so we leave our probability-weighted NPV (rNPV) for ILA unchanged at $1.24/share.